JP2018528439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528439A5 JP2018528439A5 JP2018525527A JP2018525527A JP2018528439A5 JP 2018528439 A5 JP2018528439 A5 JP 2018528439A5 JP 2018525527 A JP2018525527 A JP 2018525527A JP 2018525527 A JP2018525527 A JP 2018525527A JP 2018528439 A5 JP2018528439 A5 JP 2018528439A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- autoimmune
- autoimmune disease
- level
- biomarker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199713P | 2015-07-31 | 2015-07-31 | |
| US62/199,713 | 2015-07-31 | ||
| PCT/US2016/044779 WO2017023781A1 (en) | 2015-07-31 | 2016-07-29 | Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528439A JP2018528439A (ja) | 2018-09-27 |
| JP2018528439A5 true JP2018528439A5 (enExample) | 2019-09-05 |
| JP6674543B2 JP6674543B2 (ja) | 2020-04-01 |
Family
ID=57885963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525527A Active JP6674543B2 (ja) | 2015-07-31 | 2016-07-29 | 抗体に基づく薬物のコンパニオン診断としての細胞結合補体活性化産物アッセイ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10067128B2 (enExample) |
| EP (1) | EP3329278A4 (enExample) |
| JP (1) | JP6674543B2 (enExample) |
| AU (1) | AU2016303499B2 (enExample) |
| CA (1) | CA2990722C (enExample) |
| IL (1) | IL256618A (enExample) |
| WO (1) | WO2017023781A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102604687B1 (ko) * | 2017-02-01 | 2023-11-20 | 삼성전자주식회사 | 이미지 센서 및 그 제조 방법 |
| AU2018333062B2 (en) | 2017-09-15 | 2022-03-17 | Beckman Coulter, Inc. | Flow based assays for therapeutics |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE479707T1 (de) | 2001-09-10 | 2010-09-15 | Univ Pittsburgh | Diagnose und aufzeichnung von systemischem lupus erythematosus und von skleroderm |
| CA2522261A1 (en) | 2003-04-16 | 2004-11-04 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification and monitoring of systematic lupus erythematosus |
| KR20060015646A (ko) | 2003-06-13 | 2006-02-17 | 유니버시티 오브 피츠버그 | 면역, 혈액 및 염증성 질환의 모니터링 방법 |
| EP2214014A1 (en) * | 2004-05-11 | 2010-08-04 | The University of Pittsburgh | Monitoring immunologic, hematologic and inflammatory diseases |
| EP1904101A4 (en) * | 2005-06-08 | 2011-06-15 | Univ Duke | ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION |
| AU2009305575A1 (en) | 2008-10-16 | 2010-04-22 | Cypress Bioscience, Inc. | Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (SLE) and other autoimmune diseases |
| WO2010054195A2 (en) | 2008-11-07 | 2010-05-14 | Centocor Ortho Biotech Inc. | Markers and methods for assessing and treating lupus patients susceptible to photoprovocation |
| US20110177531A1 (en) | 2009-10-16 | 2011-07-21 | Exagen Diagnostics, Inc. | Cell-Based Complement Activation Product Algorithm for Diagnosing Systemic Lupus Erythematosus |
| US10132813B2 (en) * | 2011-02-11 | 2018-11-20 | Exagen Diagnostics, Inc. | Methods for diagnosing systemic lupus erythematosus |
| WO2013090636A1 (en) | 2011-12-13 | 2013-06-20 | Baxter International Inc. | Measurement of autoantibodies at low conductivity conditions with increased sensitivity |
| WO2014020357A1 (en) | 2012-08-02 | 2014-02-06 | Sense Proteomic Limited | Auto-antigen biomarkers for lupus |
| WO2014093268A1 (en) | 2012-12-10 | 2014-06-19 | Allegheny-Singer Research Institute | Methods and systems for using complement-tagged molecules as biomarkers of disease |
| RU2019103573A (ru) * | 2013-02-08 | 2019-03-15 | Аллегени-Сингер Рисерч Инститьют | Клеточно-связанные продукты активации комплемента в качестве диагностических биомаркеров волчанки в доклинической стадии |
| WO2015105973A1 (en) * | 2014-01-08 | 2015-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF |
| RU2017107273A (ru) | 2014-08-08 | 2018-09-10 | Аллегени-Сингер Рисерч Инститьют | Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров |
-
2016
- 2016-07-29 EP EP16833629.5A patent/EP3329278A4/en active Pending
- 2016-07-29 WO PCT/US2016/044779 patent/WO2017023781A1/en not_active Ceased
- 2016-07-29 US US15/223,906 patent/US10067128B2/en active Active
- 2016-07-29 CA CA2990722A patent/CA2990722C/en active Active
- 2016-07-29 AU AU2016303499A patent/AU2016303499B2/en active Active
- 2016-07-29 JP JP2018525527A patent/JP6674543B2/ja active Active
-
2017
- 2017-12-27 IL IL256618A patent/IL256618A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hervier et al. | Clinical heterogeneity and outcomes of antisynthetase syndrome | |
| Kothur et al. | Utility of CSF cytokine/chemokines as markers of active intrathecal inflammation: comparison of demyelinating, anti-NMDAR and enteroviral encephalitis | |
| Zhao et al. | Plasma levels of IL-37 and correlation with TNF-α, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis | |
| Munroe et al. | Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare | |
| Zhang et al. | Serum IgG subclasses in autoimmune diseases | |
| Allenbach et al. | Th1 response and systemic treg deficiency in inclusion body myositis | |
| Van Baarsen et al. | The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis | |
| Liu et al. | Correlation of interferon‐inducible chemokine plasma levels with disease severity in systemic sclerosis | |
| Feng et al. | Identification of interferon-inducible genes as diagnostic biomarker for systemic lupus erythematosus | |
| Bonella et al. | Biomarkers in connective tissue disease-associated interstitial lung disease | |
| Kopetschke et al. | The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers | |
| Guerrier et al. | Proinflammatory B-cell profile in the early phases of MS predicts an active disease | |
| Narayanan et al. | Correlation between systemic lupus erythematosus disease activity index, C3, C4 and anti-dsDNA antibodies | |
| Hu et al. | Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus | |
| Yao et al. | Adult autoinflammatory disease frequency and our diagnostic experience in an adult autoinflammatory clinic | |
| Snir et al. | Genetic variation in the serotonin receptor gene affects immune responses in rheumatoid arthritis | |
| Tamer et al. | Coexistence of autoimmune diseases and autoantibodies in patients with myasthenia gravis | |
| Kuuliala et al. | Constitutive STAT3 phosphorylation in circulating CD4+ T lymphocytes associates with disease activity and treatment response in recent-onset rheumatoid arthritis | |
| Chan et al. | Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: is microRNA-146 all we need? | |
| Zhang et al. | Genotype characteristics and immunological indicator evaluation of 311 hemophagocytic lymphohistiocytosis cases in China | |
| Raymond et al. | Principal component analysis reveals disconnect between regulatory cytokines and disease activity in Systemic Lupus Erythematosus | |
| Guo et al. | Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment | |
| Wen et al. | Detection of dynamic frequencies of Th17 cells and their associations with clinical parameters in patients with systemic lupus erythematosus receiving standard therapy | |
| Murakami et al. | Human CD4+ T cells regulate peripheral immune responses in rheumatoid arthritis via insulin-like growth factor–like family member 2 | |
| Cordiali-Fei et al. | Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease |